{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:31:47Z","timestamp":1777465907892,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SHOWA Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor-positive, HER2-negative (HR\u2009+\u2009\/HER2-) breast cancer generally has a favorable prognosis; however, early postoperative recurrence markedly reduces survival. Accurate prediction of early recurrence is crucial for personalizing treatment. This case\u2013control study compared MammaPrint (MP) and BluePrint (BP) results between early recurrence patients and matched controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were selected from our previous study, the WJOG15721B cohort (n\u2009=\u20092732). Those with recurrence within three years after surgery were randomly extracted, and controls matched for institution, clinical stage, and number of pathological lymph node metastases were included (n\u2009=\u2009124). Tumor samples underwent MP and BP assays to classify recurrence risk and molecular subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 115 submitted tumor samples, 85 were analyzed successfully (43 early recurrence, 42 no recurrence). High-risk MP classification was significantly more frequent in early recurrence patients (79.1% vs. 40.5%, p\u2009&lt;\u20090.001), and Luminal B BP subtype was more common in early recurrence patients (79.1% vs. 38.1%, p\u2009&lt;\u20090.001). High MP risk was associated with high Ki-67 levels and higher nuclear grade. Integrating clinical and genomic risk enhanced prognostic precision: patients with both clinical and genomic high risk had the highest recurrence rate (100%), those with low clinical and genomic risk had the lowest (28.1%), and patients with low clinical but high genomic risk showed an intermediate recurrence rate (57.5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP\/Luminal B BP subtype suggested an association with early recurrence in patients with HR\u2009+\u2009\/HER2- early breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-026-01847-2","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:55:20Z","timestamp":1774518920000},"page":"693-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of a multigene assay (MammaPrint\/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case\u2012control study (WJOG16722B)"],"prefix":"10.1007","volume":"33","author":[{"given":"Rurina","family":"Watanuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-9121","authenticated-orcid":false,"given":"Hitomi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsue","family":"Uehiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Kamio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"1847_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12282-016-0730-3","volume":"24","author":"A Ogiya","year":"2017","unstructured":"Ogiya A, Yamazaki K, Horii R, Shien T, Horimoto Y, Masuda N, et al. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer. 2017;24:473\u201382.","journal-title":"Breast Cancer"},{"key":"1847_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-025-01700-y","author":"R Watanuki","year":"2025","unstructured":"Watanuki R, Sakai H, Takehara Y, Yoshida A, Hayashi N, Ozaki Y, et al. Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B). Breast Cancer. 2025. https:\/\/doi.org\/10.1007\/s12282-025-01700-y.","journal-title":"Breast Cancer"},{"key":"1847_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717\u201329.","journal-title":"N Engl J Med"},{"key":"1847_CR4","doi-asserted-by":"crossref","unstructured":"Piccart M, van \u2019t Veer LJ, Poncet C, Cardozo JMNL, Delaloge S, Pierga JY, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021; 22: 476\u2013488.","DOI":"10.1016\/S1470-2045(21)00007-3"},{"key":"1847_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-011-1683-z","volume":"133","author":"O Krijgsman","year":"2012","unstructured":"Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133:37\u201347.","journal-title":"Breast Cancer Res Treat"},{"key":"1847_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100756","volume":"13","author":"L Mittempergher","year":"2020","unstructured":"Mittempergher L, Delahaye LJMJ, Witteveen AT, Snel MHJ, Mee S, Chan BY, et al. Performance characteristics of the Blueprint\u00ae breast cancer diagnostic test. Transl Oncol. 2020;13:100756.","journal-title":"Transl Oncol"},{"key":"1847_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s12282-015-0649-0","volume":"23","author":"H Yamashita","year":"2016","unstructured":"Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, et al. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2016;23:830\u201343.","journal-title":"Breast Cancer"},{"key":"1847_CR8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/cncr.23320","volume":"112","author":"H Kennecke","year":"2008","unstructured":"Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, et al. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer. 2008;112:1437\u201344.","journal-title":"Cancer"},{"key":"1847_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"1847_CR10","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","volume":"32","author":"N Harbeck","year":"2021","unstructured":"Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32:1571\u201381.","journal-title":"Ann Oncol"},{"key":"1847_CR11","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987\u201398.","journal-title":"J Clin Oncol"},{"key":"1847_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111\u201321.","journal-title":"N Engl J Med"},{"key":"1847_CR13","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","volume":"380","author":"JA Sparano","year":"2019","unstructured":"Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380:2395\u2013405.","journal-title":"N Engl J Med"},{"key":"1847_CR14","doi-asserted-by":"crossref","unstructured":"van \u2019t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530\u2013536.","DOI":"10.1038\/415530a"},{"key":"1847_CR15","doi-asserted-by":"crossref","unstructured":"van de Vijver MJ, He YD, van \u2019t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347: 1999\u20132009.","DOI":"10.1056\/NEJMoa021967"},{"key":"1847_CR16","doi-asserted-by":"crossref","unstructured":"Buyse M, Loi S, van \u2019t Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183\u20131192.","DOI":"10.1093\/jnci\/djj329"},{"key":"1847_CR17","doi-asserted-by":"crossref","unstructured":"Viale G, de Snoo FA, Slaets L, Bogaerts J, van \u2019t Veer L, Rutgers EJ, et al. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma: outcome results from the EORTC 10041\/BIG 3\u201304 MINDACT trial. Breast Cancer Res Treat. 2018; 167: 123\u2013131.","DOI":"10.1007\/s10549-017-4509-9"},{"key":"1847_CR18","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1245\/s10434-022-11666-2","volume":"29","author":"P Whitworth","year":"2022","unstructured":"Whitworth P, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, et al. Age-independent preoperative chemosensitivity and 5-year outcome determined by combined 70- and 80-gene signature in a prospective trial in early-stage breast cancer. Ann Surg Oncol. 2022;29:4141\u201352.","journal-title":"Ann Surg Oncol"},{"key":"1847_CR19","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2022.2565","volume":"17","author":"JE Amezcua-G\u00e1lvez","year":"2022","unstructured":"Amezcua-G\u00e1lvez JE, Lopez-Garcia CA, Villarreal-Garza C, Lopez-Rivera V, Canavati-Marcos M, Santuario-Facio S, et al. Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. Mol Clin Oncol. 2022;17:132.","journal-title":"Mol Clin Oncol"},{"key":"1847_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.511","volume":"42","author":"J O\u2019Shaughnessy","year":"2024","unstructured":"O\u2019Shaughnessy J, Graham CL, Whitworth P, Beitsch PD, Osborne CRC, Rahman RL, et al. Association of MammaPrint index and 3-year outcome of patients with HR+HER2\u2212 early-stage breast cancer treated with chemotherapy with or without anthracycline. J Clin Oncol. 2024;42:511.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01847-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01847-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:26:58Z","timestamp":1777382818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01847-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1847"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01847-2","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hitomi Sakai has received personal honoraria and institutional research grant from Eli Lilly, and honoraria from Daiichi Sankyo, Gilead Sciences, and Astra Zeneca. Atsushi Yoshida has received honoraria from Daiichi Sankyo, Pfizer, Chugai Pharmaceutical Co., Ltd., Limited, Exact Sciences Corporation, AstraZeneca PLC, and Eisai Co., Ltd. Yukinori Ozaki has received honoraria for lectures from Daiichi Sankyo, Pfizer, Kyowa Kirin, Eli Lilly and Chugai Pharmaceutical Co., Ltd. Mayumi Iida is an employee of Eli Lilly Japan, and minor stockholders of Eli Lilly and Company. Tsutomu Kawaguchi is an employee of Eli Lilly Japan, and minor stockholders of Eli Lilly and Company.\u00a0Masashi Wakabayashi has received honoraria from Nihon Medi-Physics Co., Ltd and Nihon Medi-Physics Co.,Ltd. Junji Tsurutani has received honoraria, research grant and advisory board member fee from Eli Lilly. Toshimi Takano has received honoraria for lectures from Eli Lilly, Daiichi Sankyo, and Gilead Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Showa University Research Ethics Review Board (July 18, 2023\/2023\u2013051-B). Written informed consent was obtained, but for cases where the patient had passed away or relocated with an unknown contact address, an opt-out procedure was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}